About Acyl-coenzyme A thioesterase 1
Acyl-coenzyme A thioesterase 1 (ACOT1) is a protein
from Homo sapiens identified by UniProt accession
Q86TX2, 421 residues long.
MolForge cross-references it against 0 known binders and
93 disease associations.
Target properties
| Protein name | Acyl-coenzyme A thioesterase 1 |
| UniProt accession | Q86TX2 |
| Gene | ACOT1 |
| Organism | Homo sapiens |
| Length | 421 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (93)
Diseases linked to this target (Open Targets).
- Generalized hypotonia · score 0.33
- blood protein measurement · score 0.16
- blood metabolite measurement · score 0.11
- platelet count · score 0.11
- phosphatidylcholine measurement · score 0.07
- Blackfan-Diamond anemia · score 0.07
- alpha thalassemia-intellectual disability syndrome type 1 · score 0.06
- Alpha-thalassemia - intellectual disability syndrome linked to chromosome 16 · score 0.06
- hemoglobin D disease · score 0.06
- Heinz body anemia · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86TX2-F1 | alphafold | PREDICTED | 96.46 | — |
Amino-acid sequence (421 residues)
MAATLILEPA GRCCWDEPVR IAVRGLAPEQ PVTLRASLRD EKGALFQAHA RYRADTLGEL DLERAPALGG SFAGLEPMGL LWALEPEKPL VRLVKRDVRT PLAVELEVLD GHDPDPGRLL CRVRHERYFL PPGVRREPVR AGRVRGTLFL PPEPGPFPGI VDMFGTGGGL LEYRASLLAG KGFAVMALAY YNYEDLPKTM ETLHLEYFEE AVNYLLSHPE VKGPGVGLLG ISKGGELCLS MASFLKGITA AVVINGSVAN VGGTLRYKGE TLPPVGVNRN RIKVTKDGYA DIVDVLNSPL EGPDQKSFIP VERAESTFLF LVGQDDHNWK SEFYANEACK RLQAHGRRKP QIICYPETGH YIEPPYFPLC RASLHALVGS PIIWGGEPRA HAMAQVDAWK QLQTFFHKHL GGHEGTIPSK V
Explore Acyl-coenzyme A thioesterase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets